Kimura Shintarou, Ichikawa Misa, Sugawara Suzuka, Katagiri Tomoko, Hirasawa Yuumi, Ishikawa Takahiro, Matsunaga Wataru, Gotoh Akinobu
Environmental Science, StateArt Incorporated, Tokyo, JPN.
Gene Therapy, StateArt Incorporated, Tokyo, JPN.
Cureus. 2022 Sep 5;14(9):e28812. doi: 10.7759/cureus.28812. eCollection 2022 Sep.
An increase in nicotinamide adenine dinucleotide (NAD) levels alleviates age-related disease progression and promotes healthy life expectancy. Several studies have demonstrated that NAD levels can be efficiently replenished via nicotinamide mononucleotide (NMN) intake; additionally, the safety of its oral ingestion has been confirmed in recent clinical trials. However, the efficacy and safety of intravenous NMN administration in humans remain unclear. Therefore, we verified its safety in 10 healthy volunteers. Intravenous administration of NMN did not affect electrocardiograms, pulse, and blood pressure, nor did it affect metabolic markers in the liver, heart, pancreas, and kidneys. These results indicate that intravenous NMN administration is safe and beneficial in humans. Furthermore, NMN administration significantly increased blood NAD levels without damaging blood cells and significantly reduced blood triglyceride (TG) levels. These findings imply that intravenous administration of NMN may lead to the prevention and treatment of diseases associated with increased TG levels, such as fatty liver and diabetes.
烟酰胺腺嘌呤二核苷酸（NAD）水平的升高可缓解与年龄相关的疾病进展，并延长健康预期寿命。多项研究表明，通过摄入烟酰胺单核苷酸（NMN）可以有效补充NAD水平；此外，其口服安全性已在近期临床试验中得到证实。然而，静脉注射NMN在人体中的疗效和安全性仍不明确。因此，我们在10名健康志愿者中验证了其安全性。静脉注射NMN对心电图、脉搏和血压没有影响，对肝脏、心脏、胰腺和肾脏的代谢指标也没有影响。这些结果表明，静脉注射NMN对人体是安全有益的。此外，注射NMN可显著提高血液中的NAD水平，且不会损害血细胞，并显著降低血液甘油三酯（TG）水平。这些发现表明，静脉注射NMN可能有助于预防和治疗与TG水平升高相关的疾病，如脂肪肝和糖尿病。
